Infect Dis Poverty 2018 Aug 13;7(1):80. Epub 2018 Aug 13.
68 Shaheed Taj Uddin Ahmed Sarani, Parasitology Laboratory, International Centre for Diarrhoeal Disease Research (icddr,b), Mohakhali, Dhaka, 1212, Bangladesh.
Background: Adverse effects of antileishmanial drugs can affect patients' quality of life and adherence to therapy for visceral leishmaniasis (VL) and post-kala-azar dermal leishmaniasis (PKDL). In Bangladesh, there are 26 treatment centers that manage leishmaniasis cases coming from 100 endemic upazilas (subdistricts) of 26 districts (these include VL, PKDL, treatment failure, and relapse VL and cutaneous leishmaniasis cases). This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs). Read More